Diligence memo · auto-generated · as of July 2, 2026
Envision Genomics, Inc.
Envision Genomics, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Envision Genomics, Inc. operates in Biotechnology, based in HUNTSVILLE.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Envision Genomics, Inc. has raised $160K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $160K on 2017-12-10.
Most recent recorded round closed around 2017-12-10.
Valuation (modeled)modeled
Provath models Envision Genomics, Inc. at approximately $8.8M (range $85K–$100M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.42× the median modeled value of Pre-Seed Biotechnology companies in 2016–2018 (152 peers) — value vs value, same stage and era. Issuer reports $0–$1M revenue while modeled below niche peers.
Financing rhythm & timingmixed
Last raise 8.6 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 3% of Biotechnology peers (4293 compared).
Modeled value ranks above 17% of those peers.
Closest niche peers: New Vital Signs, Inc., Cerebral Magnetics INC, NutriBand Inc., Jivana Biotechnology Inc, AnTolRx, Inc..
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.